Peptide– tag –
-
Boehringer Ingelheim’s First-in-Class Obesity Drug BI 3034701 Enters Phase II, Triggers €10M Milestone Payment to Gubra
Boehringer Ingelheim Germany Overview Boehringer Ingelheim has initiated a Phase II clinical trial for BI 3034701, a potential first-in-class GLP-1/GIP/NPY2 triple receptor agonist for patients with obesity and overweight. This investiga... -
Eli Lilly’s Foundayo (orforglipron) Receives FDA Approval, Ushering in a New Era of Oral GLP-1 RAs for Obesity Treatment
2 Minute Medicine USA Overview On April 1, 2026, Eli Lilly's Foundayo (orforglipron) gained FDA approval for obesity treatment, marking the first non-peptide oral GLP-1 receptor agonist without food or water timing restrictions. This bre... -
Boehringer Ingelheim Announces Promising Interim Phase 2 Results for Obesity Treatment BI 3034701: A Potential First-in-Class Triple Receptor Agonist
Boehringer Ingelheim Germany Overview Boehringer Ingelheim announced promising interim results from its Phase 2 clinical trial for BI 3034701, a novel triple receptor agonist for obesity. BI 3034701, targeting GLP-1, GCG, and GIP recepto... -
2026 GLP-1 Agonist Pipeline Highlights Oral Orforglipron Approval and Retatrutide’s >28% Weight Reduction
Drug Discovery News USA Overview The 2026 GLP-1 agonist clinical pipeline is focusing on enhanced weight loss efficacy through novel mechanisms. Notably, Eli Lilly's oral small-molecule GLP-1 receptor agonist, orforglipron, received FDA ... -
The Rise of Oral GLP-1 Receptor Agonists: Transforming Diabetes and Obesity Treatment Convenience from Injections to Pills
Pharmacy Times USA Overview The advent of oral GLP-1 receptor agonists (GLP-1RAs) is fundamentally transforming drug administration in diabetes and obesity treatment. Oral formulations are rapidly gaining traction in the previously injec... -
Asahi Kasei’s Novel Forward Osmosis–Membrane Distillation System Installed at Peptistar API Manufacturing Facility to Reduce Pharmaceutical Manufacturing Time for Thermolabile Peptides and Oligonucleotides, Advancing Towards GMP Production
Asahi Kasei Japan Overview Asahi Kasei has implemented a novel forward osmosis–membrane distillation (FO-MD) system at Peptistar's API manufacturing facility to shorten production times for thermolabile APIs like peptides and oligonucleo... -
Oral GLP-1 Agonist Semaglutide Success Drives Peptide Drug Discovery Transformation: AI Design, Unnatural Amino Acids, and Nanocarriers Enhance Oral Bioavailability
Bhunia Lab Unknown Overview While peptide therapeutics have advanced significantly, oral delivery remains a challenge. The success of oral semaglutide demonstrates how chemical modifications like amino acid substitutions and fatty acid a... -
Constructive Bio Develops Oral Peptide Pipeline with Novel Membrane Permeability via Unnatural Amino Acids, Advancing ADCs with Genetic Code Expansion for Injectable-to-Oral Shift
Constructive Bio Unknown Overview Constructive Bio is developing a pipeline of oral peptide therapeutics using unnatural amino acids to enable oral bioavailability for drugs previously requiring injection. These engineered peptides featu... -
Hatch BioFund Invests in Optimeos Life Sciences: Coated Inverse Nanocarriers Achieve Over 90% Encapsulation Efficiency for Therapeutic Macromolecules
RegMedNet USA Overview Venture capital firm Hatch BioFund has invested in Optimeos Life Sciences, a Princeton University spinout, backing its proprietary nanoparticle platform for intracellular delivery of therapeutic macromolecules. Opt... -
Novo Nordisk’s Oral Wegovy Approved in UK, Becoming Europe’s First Oral GLP-1 Obesity Treatment
Clinical Research News UK Overview Novo Nordisk's oral GLP-1 receptor agonist, Wegovy (semaglutide tablet), has received approval in the UK, marking its entry as the first oral obesity medication in Europe. This approval is expected to s...
